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ABSTRACT

To assess the regulation of mammary cell activity, survival, and proliferation by prolactin (PRL), 5 Holstein
cows in early lactation received daily i.m. injections of
1 mg of quinagolide, a suppressor of PRL release, for 9
wk, whereas 4 control cows received the vehicle (water)
only. During the last week of treatment, one udder half
was milked once a day (1×) and the other twice a day
(2×). Mammary biopsies were harvested 1 wk before
and 4 and 8 wk after the start of quinagolide treatment.
The quinagolide injections reduced milk yield and resulted in lower levels of κ-casein and α-lactalbumin
mRNA in the mammary biopsies at wk 4 compared
with the control cows. In the mammary tissue of the
quinagolide-treated cows at wk 8 of treatment, cell proliferation (as determined by proliferating cell nuclear antigen labeling) was lower and apoptosis (as determined
by the terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling assay) was higher than in the
mammary tissue of the control cows. During differential milking, mammary epithelial cells (MEC) were
extracted from the milk by centrifugation and purified
by immunocytochemical binding to allow variations in
the levels of mammary transcripts to be observed. After
9 wk of treatment, levels of α-lactalbumin and κ-casein
mRNA were lower in the MEC isolated from milk of
the quinagolide-treated cows. This effect was associated
with lower PRL receptor mRNA levels and a tendency
toward lower viability in the milk-isolated MEC from
the 2×-milked glands. The decrease from 2× milking
to 1× milking also downregulated α-lactalbumin and
κ-casein transcripts in the milk-isolated MEC. Viability
was higher for the MEC collected from the 1×-milked
udder halves compared with the 2×-milked halves. In

Received April 18, 2011.
Accepted September 9, 2011.
1
Corresponding author: Marion.Boutinaud@rennes.inra.fr

conclusion, the reduction in milk yield after chronic
administration of the PRL-release inhibitor quinagolide
is associated with a reduction in mammary cell activity, survival, and proliferation in lactating dairy cows.
Reduced milking frequency was also associated with a
decrease in MEC activity.
Key words: prolactin, proliferation, apoptosis, milk
mammary epithelial cell
INTRODUCTION

Milk production depends on both the activity and the
number of mammary epithelial cells (MEC). Changes
in the number of cells in the mammary gland during
lactation are caused by mammary cell turnover resulting from 2 opposing mechanisms, cell proliferation and
cell death (mainly through apoptosis). The decline in
milk production after the peak of lactation appears to
be due to a gradual reduction in the number of milksecreting cells, given that the rate of proliferation is
lower than the rate of apoptosis (Knight and Wilde,
1987; Capuco et al., 2003). The mechanisms that are
responsible for the variations in the activity and number of mammary cells during lactation are still poorly
understood in ruminants.
Prolactin (PRL), whose release by pituitary lactotrophs is enhanced after teat stimulation at milking,
is the hormone traditionally presumed to play a major
role in the maintenance of lactation. In rodents and
rabbits, the inhibition of PRL release during lactation was found to clearly inhibit lactation (Taylor and
Peaker, 1975; Travers et al., 1996). In contrast, studies
performed in cows and goats showed controversial results regarding the galactopoietic role of PRL in these
species (Knight, 2000). Thus, in ruminants, the role of
PRL during lactation had not been clear until a recent
experiment using an efficient inhibitor of PRL release,
the dopamine D2 receptor agonist quinagolide, showed
that PRL potentially plays a role in the maintenance
of lactation (Lacasse et al., 2011). However, the mecha-
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nism by which the PRL inhibitor reduces milk production remains to be determined.
Although the in vivo evidence for a galactopoietic
role of PRL in ruminants is scarce, PRL clearly modulates the activity and number of ruminant mammary
cells in vitro. Prolactin stimulates the synthesis of milk
in ruminant mammary explants or cultivated MEC
(Skarda et al., 1982; Choi et al., 1988). Prolactin also
stimulates the proliferation of bovine MEC (Olazabal
et al., 2000) and protects them from apoptosis (Accorsi
et al., 2002). Despite those findings, the role of PRL
in mammary cell activity, survival, and proliferation
has not yet been clearly shown in vivo. Indeed, the
administration of PRL did not modify cell turnover in
bovines (Wall et al., 2006). Our assumption is that, in
ruminants, supplementation of the basal level of PRL
by exogenous administration is not able to modify
mammary functions, whereas endogenous PRL release
at milking modulates the activity and number of mammary cells.
Reducing milking frequency from twice daily (2×)
to once daily (1×) was shown to cause a 10 to 30%
decrease in milk yield associated with changes in MEC
activity (Littlejohn et al., 2010; Ben Chedly et al.,
2011). Indeed, the reductions in milk, lactose, protein,
and fat yields caused by 1× milking are clearly associated with a reduction in milk protein mRNA levels
(Ben Chedly et al., 2011). The reduction in milk yield
caused by PRL inhibition could be triggered by similar
cellular mechanisms.
We are interested in gaining a better understanding of the effect of milking-induced PRL release on
mammary gland functions. To assess the effect of PRL,
we inhibited its secretion with quinagolide injections.
The purpose of this study was to evaluate whether
PRL acted on the activity, survival, and proliferation
of epithelial cells in the bovine mammary gland and
whether the reduction to 1× milking triggered similar
mechanisms.
MATERIALS AND METHODS
Animals and Experimental Procedures

All the procedures used on animals were approved
by the animal care committee of the French Ministry
of Agriculture in accordance with French regulations
(Decree No. 2001-464; May 29, 2001).
The experimental design and procedures were described by Lacasse et al. (2011). Briefly, 10 Holstein
cows at 62 ± 4 DIM and housed at the Mejusseaume
experimental farm of the Institut national de la recherche agronomique (INRA, Le Rheu, France) were milked
Journal of Dairy Science Vol. 95 No. 1, 2012

twice a day for a 9-wk period that consisted of a 1-wk
pretreatment period and 8 wk of treatment. During wk
9 of treatment, the cows were subjected to 1 wk of differential milking (1× milking in one udder half and 2×
milking in the other half).
During the 9-wk treatment period, 5 of the cows
received daily (at 1000 h) i.m. injections of 1 mg of
quinagolide (Ferring, Wallisellen, Switzerland) diluted
in water, and the other 5 cows received water injections
(control). One multiparous cow was withdrawn from
the control group for health reasons.
Mammary Biopsies

Biopsies were taken from the upper portion of the
mammary gland 1 wk before and 4 and 8 wk after
the start of quinagolide treatment. The first 2 mammary biopsies were obtained using a 12-gauge, 10-cm,
22-mm Bard Monopty disposable core biopsy instrument (Bard, Voisins-le-Bretonneux, France), and the
last biopsy, at 8 wk, was obtained using the 70 × 4
mm instrument described by Farr et al. (1996). Before
the tissue biopsies, local anesthesia was applied by s.c.
injection of 40 mg of Xylocaine (Astra France, RueilMalmaison, France). A skin incision was performed with
a scalpel. The 22-mm core instrument was inserted 2 or
3 times to obtain sufficient tissue, whereas the 70-mm
instrument was inserted only once. After the tissue collection using the 70-mm instrument, a 4- × 5-cm plug
of absorbable hemostat (Surgicel, Johnson & Johnson
Medical, Ethicon, Issy-les-Moulineaux, France) was
inserted into the wound using a syringe (Terumo 6%
Luer, Fisher Bioblock, Illkirch-Graffenstaden, France).
A soft gauze pad was applied with pressure to the udder to control hemorrhage. The skin incision was closed
with a disposable skin stapler (Royal 35W, Clinique
Vétérinaire, Saint-Grégoire, France). The cows received
an antibiotic by means of an i.m. injection of 0.6 g of
Excenel (Pfizer Santé Animale, Paris, France) for 3 d.
Mammary tissues obtained 1 wk before and 4 wk
after the start of quinagolide treatment were used for
RNA extraction only. The biopsies performed after 8
wk were rinsed in sterile saline solution to remove all
traces of blood and cut into 2 parts, one of which was
immediately frozen in liquid nitrogen and stored at
−80°C for separate RNA, DNA, and protein analyses.
The other part was washed in PBS and fixed in 4%
paraformaldehyde for immunohistochemical analysis.
The fixed tissue was cryoprotected by incubation for
48 h in a 40% sucrose solution and then coated with
Tissue-Tek O.C.T. compound (Sakura Finetek Europe,
LaboNord, Templemars, France), frozen in a cooled
bath of isopenthane, and stored at −80°C until use.
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Isolation of MEC from Milk

Milk epithelial cells were prepared once during the
differential milking period. Milk from the morning
milking was collected separately for each udder half
to prepare total milk cells. Then, epithelial cells were
isolated from total milk cells as described previously
by Boutinaud et al. (2008), with some modifications.
Briefly, 2.3 kg of fresh milk was defatted by 15 min
of centrifugation at 1,500 × g at 4°C in several 230mL tubes (VWR International, Fontenay-sous-Bois,
France). The skim milk was removed, and the remaining
total cell pellet was resuspended and pooled in 150 mL
of PBS (Gibco, Invitrogen, Cergy Pontoise, France).
The cell suspension was washed twice in PBS, filtered,
and finally resuspended in 2 mL of PBS containing 1%
BSA (Sigma Aldrich, Lyons, France). This cell suspension was analyzed for cell count and viability determinations using Kova slides (CLM, Nemours, France)
under light microscopy and a Vi-CELL XR analyzer
(Beckman Coulter, Roissy, France). The 1% BSA-PBS
cell suspension was used for MEC isolation with an
immunomagnetic separation technique. Briefly, Dynabeads (Pan Mouse IgG, Dynal Biotech, Invitrogen)
were first coated with a primary mouse monoclonal
antibody directed against cytokeratin 8 antibody (clone
K8.13, Sigma Aldrich). Each cell sample was incubated
with the bead and antibody mix. After 1 h of incubation, the samples were placed in a magnetic particle
concentrator (MPC-S, Dynal Biotech, Invitrogen), and
the supernatant containing the nonselected cells was
removed. The isolated MEC were resuspended in 1 mL
of 1% BSA-PBS. This cell suspension was analyzed for
cell count and viability determinations. The MEC were
pelleted by centrifugation (5 min, 4°C, 5,000 × g), and 1
mL of Trizol (Invitrogen Life Technologies) was added.
The cell samples were mixed and stored at −80°C until
total RNA extraction was performed.
Real-Time Reverse-Transcription PCR

Extraction of total RNA from the mammary tissue
samples and milk-isolated MEC samples was performed
as previously reported (Boutinaud et al., 2008). The
concentration of total RNA was analyzed by spectrophotometry, and the integrity of total RNA given by
the RNA integrity number was checked using a 2100
Bioanalyzer (Agilent Technologies, Massy, France).
Treatment of total RNA samples (from 500 ng for both
types of samples) for reverse transcription and realtime PCR analysis using SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA) was carried
out as described previously (Boutinaud et al., 2008).
The primers used for real-time PCR for proliferating

cell nuclear antigen (PCNA), (forward 5c-TTTGCACGTATATGCCGAGATC-3c; reverse 5c-TATGGCAACAGCTTCCTCCTC-3c), for PRL receptor
(PRLR) long isoform (forward 5c-TGCTGTCATCTGTTTGATTATGGTC-3c; reverse 5c-TTGCTCCGTGTGTTCTTTGG-3c), and for PRLR short isoform
(forward 5c-GCTATAGCATGGTGACCTGCATC-3c;
reverse
5c-CGGACTTGCCCTCCTATTAAAAC-3c)
were designed using the Primer Express 1.0 software
program (Applied Biosystems) and synthesized by
MWG Biotech (Roissy, France). The other primers
used were described in previous studies (Boutinaud
et al., 2008; Ben Chedly et al., 2009). For each gene
analyzed, a standard curve made with serial dilutions
of one sample of mammary gland reverse transcript was
used to quantify the mRNA levels. The mRNA levels
of the studied genes were expressed relative to a housekeeping gene. The genes cyclophilin, R18S, GAPDH,
and ribosomal protein large P0 (RPLP0) were evaluated as potential housekeeping genes. The BestKeeper
(Pfaffl et al., 2004) and NormFinder (Andersen et al.,
2004) programs were used to assess the variability
of the candidate housekeeping genes. These analyses
indicated that RPLP0 was the most stable housekeeping gene in this experiment. For each gene, the mRNA
level was expressed as a semi-absolute mRNA molecule
number (Boutinaud et al., 2004). For each target gene,
the results were expressed as a ratio using the selected
housekeeping gene, namely RPLP0.
Protein Extraction and Western Blot Analysis

Total and nuclear proteins were extracted from frozen mammary gland tissues after 8 wk of quinagolide
treatment. Total proteins were extracted using T-PER
Tissue Protein Extraction Reagent (Pierce, Perbio
Science, Brebières, France). Frozen mammary tissue
samples (15 mg) were homogenized in 40 volumes (wt/
vol) of T-PER lysis buffer using an Ultra-Turrax homogenizer (Fisher Bioblock) as recommended by the
manufacturer. After centrifugation at 10,000 × g for
5 min at 4°C, the supernatant containing the total
protein extracts was recovered and quickly frozen. To
obtain nuclear protein extracts, frozen mammary tissue samples (20 mg) were homogenized in 5 volumes
(wt/vol) of Cytoplasmic Extraction Reagent I from the
NE-PER Nuclear and Cytoplasmic Extraction Reagent
Kit (Pierce) using an Ultra-Turrax homogenizer. After
the tubes were vortexed vigorously, the lysates were
incubated on ice for 10 min. Cytoplasmic Extraction
Reagent II (5%) was added to the lysates to disrupt the
cell membranes and release the cytoplasmic contents.
The intact nuclei were recovered from the cytoplasmic
extract by centrifugation at 13,000 × g for 5 min at
Journal of Dairy Science Vol. 95 No. 1, 2012
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4°C. The pellet was resuspended in 100 μL of ice-cold
Nuclear Extraction Reagent. The tubes were vortexed
and incubated on ice for 40 min as recommended by
the manufacturer. The nuclear preparation was cleared
by centrifugation at 13,000 × g for 10 min. The supernatant containing the nuclear extract was quickly
frozen. The protein concentration was determined by
the Lowry method using the DC Protein Assay Kit
(Pierce) as described by the manufacturer. Then, the
protein lysates were combined with sample buffer containing 50 mM Tris-HCl, pH 6.8 (Bio-Rad, Marnesla-Coquette, France), 2% SDS, 0.1% bromophenol
blue (Sigma Aldrich), 20% glycerol (Fisher Scientific
Bioblock), and 5% β-mercaptoethanol (Sigma Aldrich),
boiled for 5 min at 95°C, and resolved by SDS-PAGE.
Proteins (30 μg per lane) and prestained molecular
mass standards (Fermentas, Saint-Rémy-lès-Chevreuse,
France) were separated on 10% SDS-polyacrylamide
gels, electro-transferred overnight to polyvinylidene
difluoride membranes (Amersham Biosciences, Orsay,
France), and incubated with blocking solution [5% dry
skim milk dissolved in Tris-buffered saline–Tween 20
(Bio-Rad), 50 mM Tris-HCl pH 8.6 (Bio-Rad), 150
mM NaCl (Sigma Aldrich), and 0.1% Tween (Sigma
Aldrich)] for 30 min. The membranes were then incubated overnight at 4°C with the appropriate dilution of
the following primary antibodies: a mouse monoclonal
anti-PCNA (clone PC10, DakoCytomation, Glostrup,
Denmark; diluted 1:5,000) and a mouse monoclonal
anti-β-actin (A5441, Sigma Aldrich; diluted 1:5,000).
Then, the membranes were washed with Tris-buffered
saline–Tween 20 before incubation with horseradish
peroxidase-conjugated anti-mouse secondary antibodies (31450, Pierce) for 1 h at room temperature.
Peroxidase activity was detected using an enhanced
chemiluminescence detection system (ECL System,
Amersham Biosciences). The membranes were exposed
to Curix Ortho HT-G films (Agfa, Mortsel, Belgium),
which were then digitized at 16-bit/600-dpi resolution
using a Canoscan D1250U2 scanner (Canon, Courbevoie, France). The images were saved as TIFF files and
calibrated to an optical density scale. The integrated
optical density of the bands was quantified using the
ImageJ software program (Wayne Rasband, National
Institutes of Health, Bethesda, MD). Each sample was
normalized according to β-actin content.
Immunohistochemistry for Proliferation
and Apoptosis Assays in Mammary Tissue Sections

Proliferating cells were identified in mammary tissue
after 8 wk of quinagolide treatment as cells expressing the PCNA antigen, as previously reported (Colitti
et al., 2005). Cryosections measuring 7 μm thick
Journal of Dairy Science Vol. 95 No. 1, 2012

were mounted onto Superfrost/Plus slides (Prolabo,
Bondoufle, France). Mammary gland sections were
quenched in PBS with 3% hydrogen peroxide and 10%
methanol for 30 min. After several washes with PBS,
the sections were permeabilized with 1% SDS-PBS for
5 min, washed 3 times in PBS, and pre-incubated in
1% BSA-PBS for 1 h at room temperature. The tissues were then incubated in the presence or absence of
a primary antibody (M0879, monoclonal mouse clone
PC10, DakoCytomation; diluted 1:200) in the same
buffer overnight at 4°C. After washes with 1% BSA/
PBS, the samples were incubated with 1:200-diluted
second antibody (F5387, goat anti-mouse fluorescein
isothiocyanate–conjugated antibody, Sigma Aldrich)
for 1 h at room temperature. Subsequently, the mammary gland sections were counterstained for 3 min
with 4c,6-diamidino-2-phenylindole (DAPI, D9542,
Sigma Aldrich) at 33 μg/mL and then for 3 min with
propidium iodide (P4864, Sigma Aldrich) at 333 μg/
mL.
The determination of apoptosis in the mammary gland
biopsies was based on DNA fragmentation detection
using terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL) staining. Cryosections measuring 7 μm thick that had been mounted
onto slides treated with 3-aminopropyltriethoxysilane
(Sigma Aldrich) were thawed and incubated for 30 min
at 70°C in a solution of 10 mM citrate sodium (Sigma
Aldrich) and 0.1% Triton (Fisher Scientific Bioblock),
washed in PBS, and incubated for 30 min at 37°C in
200 ng/μL proteinase K solution (Promega, Madison,
WI). The tissue sections were incubated with reagents
from the DeadEnd Fluorometric TUNEL System (Promega) according to the manufacturer’s instructions.
After the TUNEL reaction was stopped, the mammary
gland sections were counterstained by incubation for 3
min with DAPI (Sigma Aldrich) at a concentration of
333 μg/mL.
After washing, the slides were mounted with Vectashield (Valbiotech, Paris, France) and examined under
fluorescence microscopy using an Eclipse E400 microscope (Nikon France, Le Pallet, France). The pictures
were captured by a DXM 1200 digital still camera
(Nikon) and analyzed with the ImageJ software. Eight
microscopic fields (magnification: 200×; area: 0.14 mm2
per microscopic field) were examined for each tissue
sample. The percentage of apoptosis or proliferation in
the mammary gland was determined as a ratio of the
TUNEL-labeled or PCNA-positive cells to the DAPIcounterstained nuclei. Epithelial cells positive for PCNA
were determined with propidium iodide staining, which
draws the outlines of the acini. For each acinus, the
ImageJ software was used to count the number of cells
and determine alveolar size.
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DNA Quantification of Mammary Tissue

Mammary tissue samples (50 mg) were first weighed
and homogenized in 2.5 mL sodium phosphate extraction buffer (0.05 M Na2HPO4, 0.05 M NaH2PO4, 2 mM
EDTA, and 2 M NaCl, pH 7.4, Sigma Aldrich). Then,
the mixture was ground using an Ultra-Turrax homogenizer, sonicated for 1 min, and centrifuged at 4,000 ×
g for 1 h. The supernatant was transferred to another
tube, and the pellet was resuspended in 2.5 mL of the
extraction buffer. Subsequently, the pellet was subjected to 3 successive extraction steps, namely grinding, sonication, and centrifugation, as described above.
At the end of each centrifugation, the supernatant was
recovered and added to the first. The DNA concentration in the mixture was determined by fluorescence
using Hoechst 33258 dye (Sigma Aldrich). Aliquots of
the DNA mixture were mixed with sodium phosphate
buffer stained with Hoechst dye to a final dye concentration of 1 μg/mL. The reactions were performed in a
200-μL final volume in a black 96-well microplate. Serial dilutions of calf thymus DNA (Sigma Aldrich) were
used to generate a standard curve. The plates were directly read with the Mithras LB940 fluorescence plate
reader (Berthold Technologies, Thoiry, France) at 355
nm excitation and 460 nm emission wavelengths. The
DNA concentrations in the mammary tissue samples
were calculated by extrapolation from the standard
curve and correction for aliquot volume.

milking frequency and quinagolide treatment. Differences were considered statistically significant when P
< 0.05.
RESULTS
Effects of Quinagolide Treatment and Differential
Milking on Milk Yield and Composition

The results for milk yield and composition were reported previously (Lacasse et al., 2011). Briefly, daily
injections of quinagolide reduced milking-induced PRL
release (P < 0.05) but not basal PRL concentration.
Quinagolide induced a faster decline in milk production
(P < 0.05) compared with the control treatment. The
milk production of the quinagolide-treated cows was
5.3 kg/d less than that of the control cows during the
last 4 wk of treatment. Milk fat, protein, and casein
contents were not affected by the treatment, whereas
lactose content was reduced (P < 0.05) in the quinagolide-treated cows in wk 5, 6, and 7. Milk fat, lactose,
and protein yields were lower in the quinagolide-treated
animals than in the controls (P < 0.05).
Differential milking resulted in modifications in milk
yield and composition. Reductions in milk production and fat and protein yields were observed in the
1×-milked udder halves (P < 0.001) compared with the
2×-milked halves. The inhibitory effect of quinagolide
was maintained in the 2×-milked udder halves (P <
0.05) but was lost in the 1×-milked halves (P > 0.15).

Statistical Analyses

The statistical analyses of the real-time PCR results
were performed on the basis of semi-absolute data
normalized individually by RPLP0 multiplied by 104
and log10-transformed. The PCR data for the biopsy
samples were analyzed by ANOVA using the MIXED
procedure of SAS (SAS Institute Inc., Cary, NC) with
a REPEATED statement. Time was used as a repeated
effect, and cow(treatment) was used as the subject.
The data for cell proliferation and apoptosis, protein
and DNA contents, and alveolar characteristics in
the mammary gland were analyzed by ANOVA using
the MIXED procedure of SAS. The proliferation rate
obtained in the entire mammary tissue was compared
with that in the MEC by testing the H0 hypothesis that
the rates did not differ using a paired Student’s t-test.
The data for the PCR results in the milk-isolated MEC
were analyzed by least squares ANOVA using the GLM
procedures in the epsilon Windows software (L. Delaby,
UMR1080, Production du lait, INRA, France). The
split-plot linear model was used to test the effects of
milking frequency, quinagolide treatment, quinagolide
treatment within the cow, and the interaction between

Transcript Levels in the Mammary Gland

Before the start of quinagolide treatment, the levels
of α-LA and κ-CN mRNA were similar between the 2
groups of animals (Table 1). After 4 wk of treatment,
quinagolide injections induced reductions in the α-LA
and κ-CN mRNA levels (−73%, P = 0.06 and −75%, P
= 0.05, respectively). The mRNA levels of these genes
were not different after 8 wk of treatment. Quinagolide
treatment had no effect on glucose transporter 1
(GLUT1), caspase 3, bax, or bcl 2 mRNA levels in the
mammary gland (Table 1). At no time did quinagolide
treatment affect PRLR long and short isoform mRNA
levels (Table 1) in the mammary tissue.
Number and Transcript Levels of Milk-Isolated MEC

Mammary epithelial cells were collected from the
1×- and 2×-milked udder halves during wk 9 of treatment. The number of milk-isolated MEC averaged 14.7
× 103 ± 4.1 × 103 cells/mL milk, representing 9.3 ±
1.9% of the total cells recovered in the milk. The total
number of cells was not affected by either quinagolide
Journal of Dairy Science Vol. 95 No. 1, 2012
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Table 1. Effect of the injection of water (control; n = 4) or quinagolide (Quin; 1 mg/d; n = 5) on mRNA levels in mammary tissue in wk −1,
4, and 8 relative to the start of treatment
Week −1
Item1
α-Lactalbumin
κ-Casein
PRLR long isoform
PRLR short isoform
GLUT1
PCNA
Caspase 3
Bax
Bcl 2
Bax/bcl 2
RPLP0

Week 4

Week 8

Control

Quin

P-value2

Control

Quin

P-value2

Control

Quin

P-value2

27,000
29,900
3.2
30.8
2.0
6.9
0.6
0.38
0.36
1.10
392,000

21,900
35,800
5.3
33.1
1.9
7.7
1.1
0.19
0.51
0.42
377,000

0.76
0.77
0.43
0.84
0.77
0.63
≤0.01
0.12
0.32
≤0.01
0.87

53,700
64,400
3.8
28.1
1.6
6.5
0.9
0.14
0.36
0.47
382,000

13,600
17,100
1.7
24.8
1.1
7.8
0.7
0.23
0.44
0.54
302,000

0.06
0.05
0.20
0.74
0.18
0.41
0.18
0.28
0.55
0.75
0.33

55,500
75,700
3.7
33.7
2.5
7.7
1.5
0.26
0.38
0.78
395,000

34,000
66,200
7.3
46.1
2.8
6.7
1.3
0.24
0.29
0.86
556,000

0.49
0.83
0.28
0.41
0.63
0.48
0.52
0.81
0.46
0.70
0.17

1

PRLR = prolactin receptor; GLUT1 = glucose transporter 1; PCNA = proliferating cell nuclear antigen; RPLR0 = ribosomal protein large P0.
Statistical analyses were performed on the semi-absolute mRNA molecule number relative to RPLP0 multiplied by 104 and log10-transformed.
Data presented are retransformed into the semi-absolute mRNA level ratio multiplied by 100, except for RPLP0, which is expressed as a semiabsolute number of molecules.
2

treatment or milking frequency. Quinagolide treatment
had no effect on the loss MEC in milk per day, whereas
this number tended to be lower in the 1×-milked udder
halves than in the 2×-milked halves (Table 2).
The viability of isolated MEC was not affected by
quinagolide but was higher for the cells collected from
the 1×-milked udder halves than for those from the
2×-milked halves (P = 0.03; Table 2). Quinagolide did
not affect MEC viability (P = 0.14; Table 2). When
the 2×-milked halves were considered alone, however,
quinagolide treatment had a tendency to reduce milkisolated MEC viability compared with the control
treatment (P = 0.08).
Total RNA recovered from the milk-isolated MEC
averaged 34.5 ± 9.1 μg. The quality and quantity of

total RNA for the milk-isolated MEC samples were
good except for one sample that was removed from the
trial (RNA integrity number <4). During the differential milking, the mRNA levels of α-LA and κ-CN were
lower in the milk-isolated MEC from both the 1×- and
2×-milked udder halves in the quinagolide-treated cows
compared with the control cows (P = 0.001 for both
genes; Table 2). Similarly, quinagolide treatment was
associated with lower levels of the PRLR long isoform
transcript (P = 0.02). This effect was significant in the
MEC from the 2×-milked udder halves (P = 0.04) but
not in the MEC from the 1×-milked halves (P = 0.12).
In contrast, the levels of the PRLR short isoform transcript were not affected by quinagolide treatment (P =
0.13). As in the mammary gland, the mRNA levels of

Table 2. Effect of injection of water (control; n = 4) or quinagolide (Quin; 1 mg/d; n = 5) and differential milking (1×, once-daily milking of
one udder half; 2×, twice-daily milking of the other udder half) on mammary epithelial cells (MEC) recovered in milk and on mRNA levels in
milk-isolated MEC during wk 9 of quinagolide treatment
2×
Item1
MEC/mL of milk
Milk MEC viability (%)
Loss of MEC in the milk (106 cells/d)
α-Lactalbumin
κ-Casein
PRLR long isoform
PRLR short isoform
GLUT1
Bax
Bcl 2
Bax/bcl 2
RPLP0

P-value2

1×

Control

Quin

Control

Quin

MF

Quin

MF × Quin

14,166
77.5ab
309
1,313a
365a
0.39a
0.13
1.65
1.75
2.44
0.71
291,000

17,799
51.3a
288
156b
41b
0.06b
0.05
1.15
2.23
2.69
0.60
300,000

14,166
91.7b
172
316b
143a
0.16ab
0.09
1.87
2.60
2.53
0.92
367,000

12,551
87.2b
131
53c
20b
0.05b
0.02
1.77
2.75
2.06
1.12
330,000

0.52
0.03
0.06
≤0.01
0.04
0.31
0.38
0.38
0.28
0.49
0.12
0.31

0.80
0.14
0.66
≤0.01
≤0.01
0.02
0.13
0.49
0.58
0.74
0.93
0.80

0.52
0.28
0.89
0.57
0.75
0.51
0.73
0.61
0.71
0.38
0.51
0.67

a–c

For significant difference according to MF × Quin treatments.
PRLR = prolactin receptor; GLUT1 = glucose transporter 1; RPLR0 = ribosomal protein large P0.
2
Statistical analyses were performed on the semi-absolute mRNA molecule number relative to RPLP0 multiplied by 105 and log10-transformed.
Data presented here are retransformed into the semi-absolute mRNA level ratio multiplied by 100, except for RPLP0, which is expressed as a
semi-absolute number of molecules. Effects: MF = milking frequency; Quin = quinagolide.
1
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GLUT1, caspase 3, bax, and bcl 2 were not affected by
quinagolide treatment in the milk-isolated MEC.
As with quinagolide treatment, milking frequency
induced variations in milk protein mRNA levels in the
milk-isolated MEC (Table 2). Transcripts of α-LA and
κ-CN were downregulated by 1× milking compared
with 2× milking (P ≤ 0.01 and P = 0.04 for α-LA
and κ-CN, respectively). The mRNA levels of the other
studied genes did not vary with milking frequency in
the milk-purified MEC.
PCNA Protein and mRNA Expression
and Proliferation Rate in the Mammary Gland

Analysis by Western blotting of PCNA protein levels
in the mammary gland tissue collected in wk 8 revealed
1 PCNA band of 36 kDa expressed in the total and
nuclear protein extracts (Figure 1). Relative PCNA
protein levels were lower in the total and nuclear protein
extracts from the quinagolide-treated cows compared
with the controls (P = 0.01 and P = 0.03, respectively).
In contrast, PCNA mRNA levels analyzed by real-time
reverse transcription PCR were not affected by quinagolide treatment (Table 2). The immunohistochemistry
analysis showed that PCNA labeling was principally
localized in the nuclei. The counting of PCNA-positive
cells indicated that the percentage of proliferation in the
mammary gland was lower in the quinagolide-treated
cows than in the controls (−50%, P = 0.02; Figure 2).
The reduction in the percentage of PCNA-positive cells
averaged −57% (P = 0.01) when only the MEC were
considered. Interestingly, the proliferation rate tended
to be higher in the MEC than in the entire mammary
gland of both groups of animals (P = 0.08).
Apoptosis, Alveolar Structure, and DNA
Concentration in the Mammary Gland

In the mammary biopsies collected after 8 wk of
treatment, the level of apoptosis determined using the
TUNEL assay was 3 times higher in the quinagolidetreated cows than in the controls (P ≤ 0.01; Figure 2).
Quinagolide treatment had no effect on the size of
the alveoli, which averaged 7,200 ± 1,360 and 7,010
± 600 μm2 (P = 0.90) for the controls and the quinagolide-treated cows, respectively. Similarly, the number
of cells per alveolus and the number of alveoli per microscopic field did not vary with quinagolide treatment,
averaging 40.5 ± 2.3 and 45.6 ± 8.3 (P = 0.61) and
6.2 ± 0.6 and 7.0 ± 0.9 (P = 0.545) for the controls
and the quinagolide-treated cows, respectively. Moreover, mammary DNA concentration did not vary with
quinagolide treatment, averaging 1.31 ± 0.15 and 1.06

± 0.70 mg/g of tissue (P = 0.32) for the controls and
the quinagolide-treated cows, respectively.
DISCUSSION

This experiment studied the mechanisms by which
quinagolide treatment reduces milk production in dairy
cows. The decrease in milk yield induced by quinagolide
treatment was accompanied by a decrease in α-LA and
κ-CN mRNA levels in the mammary biopsies after 4
wk of treatment. The effects of quinagolide on milk
protein transcripts may be responsible for the reduced
synthesis of milk protein and lactose. Incidentally, protein and lactose yields were lower in the quinagolidetreated cows. The effect of quinagolide treatment on
lactose secretion via the downregulation of the α-LA
gene, which encodes the coenzyme of lactose synthase,
could explain, in part, the lower milk production with
quinagolide, given that lactose is the major osmotic
agent in milk and therefore a regulator of milk volume. The downregulation of milk protein transcripts
is a good indication that mammary cell activity was
decreased by quinagolide.
The effect of quinagolide on milk protein transcripts
is probably due to the inhibition of the milking-induced
PRL release (Lacasse et al., 2011). Previous studies
reported that PRL stimulates milk protein expression
in bovine MEC (Choi et al., 1988) and that PRL injections enhance α-LA mRNA expression in the mammary gland of dairy cows in early lactation (Wall et al.,
2006). It is well established that the peak of PRL at
parturition is necessary for the initiation of lactation.
Suppression of the PRL surge at parturition inhibits
mammary cell differentiation and lactogenesis (Akers
et al., 1981a,b). Therefore, the milking-induced PRL
release may help maintain the differentiation state of
mammary cells during lactation.
Although the effect of quinagolide on milk production was still present, the effect on milk protein mRNA
in the mammary tissue was no longer significant after 8
wk of treatment. Conversely, lower levels of α-LA and
κ-CN mRNA were still observed in the milk-isolated
MEC from the quinagolide-treated cows compared with
the controls after 9 wk of treatment. In contrast to
milk-isolated MEC, the mammary tissue contains other
types of cells (myoepithelial cells, endothelial cells, adipocytes, and fibroblasts), and the extraction of RNA
from the mammary tissue may dilute the mammary
transcripts of interest among transcripts from other
types of cells. Thus, the purification of MEC from milk
could constitute a more accurate method than the collection of mammary tissue for observing small variations in transcript levels. Thus, the lack of significant
Journal of Dairy Science Vol. 95 No. 1, 2012
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Figure 1. Western blot analyses of proliferating cell nuclear antigen (PCNA) and β-actin in total (panel A) and nuclear (panel B) protein
extracts from the mammary gland of cows treated (n = 5) or not (n = 4) with quinagolide for 8 wk. The integrated optical density of bands was
quantified using the ImageJ software program (National Institutes for Health, Bethesda, MD) and normalized to β-actin. The bars represent the
mean ± SEM for each type of protein extract for the control cows and the quinagolide-treated cows. *P < 0.03.

effect of the PRL inhibitor on milk protein mRNA
levels after 8 wk of treatment could be attributed to
the difficulty inherent in analyzing mRNA variations in
a complex tissue.
Because glucose, the major precursor for lactose synthesis, is actively transported into the mammary cells,
it is possible that reduced expression of the main mammary glucose transporter, GLUT1, is involved in the
reduction of lactose synthesis. In rats, PRL deprivation
induced a 40% decrease in the GLUT1 protein level in
the mammary gland plasma membrane, whereas the
mRNA level was not affected (Fawcett et al., 1992).
Although quinagolide treatment decreased lactose
Journal of Dairy Science Vol. 95 No. 1, 2012

yield and content, it had no effect on GLUT1 mRNA
expression in either mammary tissue or milk-purified
epithelial cells. Our results suggest that the regulation
of lactose synthesis by PRL does not involve the transcriptional regulation of GLUT1.
The second mechanism examined to explain the
effect of quinagolide treatment on milk production
was the evolution of cell turnover in the mammary
gland. The PCNA level is an indicator of the rate of
cell proliferation. Quinagolide treatment reduced the
amount of PCNA protein, suggesting a lower rate of
cell proliferation in the mammary gland. This result
is in accordance with the proliferative effect of PRL

PROLACTIN INHIBITION AND MAMMARY FUNCTIONS

Figure 2. Proliferation (A) and apoptosis (B) in the mammary
tissue of control cows (n = 4) and quinagolide-treated cows (n =
5) for 8 wk. The mammary gland sections were first incubated with
mouse anti–proliferating cell nuclear antigen antibody and a secondary
fluorescein isothiocyanate–conjugated anti-goat antibody and stained
with propidium iodide to draw the outline of the epithelium and with
4c,6-diamidino-2-phenylindole to counterstain the nuclei (panel A).
The mammary gland sections were labeled by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay and
stained with 4c,6-diamidino-2-phenylindole to counterstain the nuclei
(panel B). *P < 0.05; **P ≤ 0.01.

observed in cultivated bovine MEC (Olazabal et al.,
2000). However, this observation is not in line with the
findings of Wall et al. (2006), who reported that in
vivo injections of exogenous PRL failed to stimulate
cell proliferation in the mammary gland in lactating
dairy cows. Exogenous PRL may not affect mammary
cell proliferation due to the saturation of PRLR, as
suggested by Plaut et al. (1987). In contrast with that
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last study, the present study found that quinagolide
treatment reduced endogenous PRL, suggesting that
endogenous milking-induced PRL release is important
for MEC proliferation during lactation.
The antiproliferative effect of quinagolide has been
confirmed by the immunohistological detection of
PCNA-positive nuclei. However, the percentage of
positive cells was higher than expected. Proliferating
cell nuclear antigen is an auxiliary protein for DNA
polymerase γ that has a long half-life, leading to persistence of staining even in cells that have recently left
proliferative status (Yu and Filipe, 1993). Given that
the overestimation of the proliferation rate is the same
for all samples, however, we believe that this staining
has biological significance.
In this experiment, the number of cells labeled by
the TUNEL assay suggests that quinagolide treatment
caused a higher level of apoptosis in the mammary
gland. In agreement, DNA laddering, a marker of cell
apoptosis, was observed in bovine mammary explants
cultured in the absence of PRL (Accorsi et al., 2002).
Our result is also in accordance with a study performed
in rats showing that injections of exogenous PRL in
animals deficient in growth hormone and PRL inhibited the appearance of DNA laddering in the mammary
gland (Travers et al., 1996). Nevertheless, the apoptotic
effect of quinagolide was not accompanied by modifications of transcripts involved in cell death, of alveolar
structures in the mammary tissue, or of matrix metalloproteinase activities (Lacasse et al., 2011), suggesting
that remodeling of mammary tissue did not occur. The
microscopic observations and DNA concentrations are
probably not sensitive enough to observe variations in
the number of cells in the mammary gland. Rather than
acting on the number of cells in the alveolus and DNA
concentration, PRL could increase the total number of
alveoli, the total amount of DNA, and the total weight
of mammary gland as was demonstrated for growth
hormone action in the mammary gland (Baldi et al.,
2002). A better indicator would have been the weight
of the mammary gland. Moreover, although the loss
of MEC in milk was not affected by it, quinagolide
treatment tended to reduce the viability of the MEC
collected. Our study provides further evidence that
milking-induced PRL release acts as a survival factor
for MEC.
Similar to quinagolide treatment, the reduction of
milking frequency from 2× to 1× induced a significant
decrease in α-LA and κ-CN mRNA levels. The downregulation of milk protein gene expression was already
shown in MEC during 1× milking in cows (Boutinaud
et al., 2008; Littlejohn et al., 2010) and goats (Ben
Chedly et al., 2011). Similarly, a trend toward higher
levels of α-LA mRNA was reported when milking freJournal of Dairy Science Vol. 95 No. 1, 2012
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quency was increased from 2 to 4 times a day (Wall et
al., 2006). The absence of an effect of milk frequency on
GLUT1 mRNA is in accordance with previous results
in cows (Boutinaud et al., 2008; Ben Chedly et al.,
2011). As reported for goats (Ben Chedly et al., 2011),
the effect of milking frequency on GLUT1 mRNA
might appear after more than 7 d of 1× milking. The
effect of 1× milking on the regulation of milk protein
mRNA expression is not the consequence of a reduced
milking-induced PRL release, given that the 2 milking
frequencies were performed on the same animal. The
effect of milking frequency in our study is due to a
local effect only. This local effect could be the consequence of a chemical agent, the feedback inhibitor of
lactation, a physical effect due to milk accumulation,
or some combination thereof (Knight et al., 1998). Such
local effects were found to be responsible for modifications in tight junction opening and increased matrix
metalloproteinase activities during 1× milking; those
modifications had not been observed with quinagolide
treatment (Lacasse et al., 2011). Thus, the effect of
1× milking acts partly through mechanisms similar to
those involved in quinagolide treatment, namely the
decrease in MEC activity.
The effect of milking frequency could be driven by
differing PRL sensitivity indicated by changes in PRLR
gene expression. The PRLR is expressed as short and
long isoforms (Binart et al., 2010), which are differentially expressed or regulated during the estrous cycle
and pregnancy (Buck et al., 1992), suggesting that the
isoforms may initiate distinct signaling pathways and
then mediate different biological effects. The PRLR
long isoform is involved in milk protein gene expression (Lesueur et al., 1991), whereas the short isoform
is shown to transmit only a mitogenic signal (Das and
Vonderhaar, 1995) and could also act as a negative
regulator (Berlanga et al., 1997; Perrot-Applanat et
al., 1997). Controversial results about the effects of
milking frequency and suckling on PRLR mRNA were
reported: PRLR mRNA was found to increase during
thrice-daily milking compared with 1× milking or with
more frequent suckling in the mammary tissue of cows
and rats (Kim et al., 1997; Bernier-Dodier et al., 2010).
In our study, however, neither the short nor the long
isoform mRNA levels were affected during 1× milking,
as was also observed with milking performed 4 times
a day (Wall et al., 2006). As suggested by Wall et al.
(2006), the effect of milking frequency on PRLR gene
expression is probably acute and could depend on the
sampling scheme.
An unexpected result in the present study was the
lower level of PRLR mRNA in the milk-isolated MEC
from the quinagolide-treated cows, although this result
was not observed in the mammary biopsy. This result
Journal of Dairy Science Vol. 95 No. 1, 2012

is in disagreement with the inverse relationship between
circulating PRL and the expression of PRLR mRNA in
the mammary gland of dry cows exposed to different
photoperiods (Auchtung et al., 2005). This discrepancy
may result from the difference between the lactating
stage and the dry stage in cows. The effect of quinagolide on PRLR may result from a lower differentiation
status of epithelial cells in the mammary gland that
are less exposed to PRL. This effect could reinforce the
effect of PRL deprivation and explain a portion of the
decrease in cell activity and the downregulation of milk
protein transcripts in the quinagolide-treated cows. The
relationship between PRLR expression in the MEC and
PRL concentration during lactation should be further
studied.
CONCLUSIONS

In this study, we have shown that the PRL-release
inhibitor quinagolide acts through the regulation of
MEC milk protein transcription and MEC survival and
proliferation in lactating dairy cows. The regulation of
milk protein transcription is also involved in short-term
milking frequency changes. This study suggests that
PRL release at milking is crucial for the maintenance
of MEC in a differentiated status in the mammary
gland of dairy cows. The specificity of quinagolide actions via PRL inhibition release should be evaluated by
testing whether PRL injections in quinagolide-treated
cows are able to restore the mammary functions. To
confirm these results, some other dopamine agonists
known to have strong inhibition effects on PRL release,
such as metergoline or cabergoline, could be tested in
the future.
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